115 results on '"Yegya-Raman, N."'
Search Results
2. P2.02-02 Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Friedes, C., additional, Iocolano, M., additional, Lee, S.H., additional, Su, W., additional, Duan, L., additional, Li, B., additional, Doucette, A., additional, Levin, W.P., additional, Cengel, K.A., additional, DiBardino, D., additional, Cohen, R., additional, Sun, L., additional, Aggarwal, C., additional, Teo, K., additional, O'Reilly, S., additional, Xiao, Y., additional, Bradley, J.D., additional, Langer, C.J., additional, and Feigenberg, S.J., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Patterns of Failure, Volume of Disease Progression, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors (ICI)
- Author
-
Friedes, C., primary, Yegya-Raman, N., additional, Iocolano, M., additional, Lee, S.H., additional, Li, B., additional, Duan, L., additional, Levin, W.P., additional, Cengel, K.A., additional, Sun, L., additional, Aggarwal, C., additional, Marmarelis, M.E., additional, Doucette, A., additional, Cohen, R., additional, Xiao, Y., additional, Langer, C., additional, and Feigenberg, S.J., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Association of Cardiac Dose with Cardiac Events and Survival for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Concurrent Chemoradiotherapy (cCRT) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation
- Author
-
Yegya-Raman, N., primary, Lee, S.H., additional, Friedes, C., additional, Iocolano, M., additional, Kim, K.N., additional, Duan, L., additional, Li, B., additional, Sun, L., additional, Cohen, R., additional, Cengel, K.A., additional, Levin, W.P., additional, Langer, C., additional, Aggarwal, C., additional, Ky, B., additional, O'Quinn, R.P., additional, Zou, W., additional, Teo, K., additional, Deasy, J.O., additional, Xiao, Y., additional, and Feigenberg, S.J., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiotherapy (IMRT) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation: A Retrospective Cohort Study
- Author
-
Iocolano, M., primary, Yegya-Raman, N., additional, Wang, X., additional, Friedes, C., additional, Lee, S.H., additional, Duan, L., additional, Li, B., additional, Levin, W.P., additional, Cengel, K.A., additional, Langer, C., additional, Cohen, R., additional, Sun, L., additional, Aggarwal, C., additional, Doucette, A., additional, Xiao, Y., additional, Teo, K., additional, O'Reilly, S.E., additional, Zou, W., additional, Simone, C.B., additional, and Feigenberg, S.J., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Interpretable Machine Learning for Predicting Symptomatic Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Immune Checkpoint Inhibitor Consolidation
- Author
-
Duan, L., primary, Lee, S.H., additional, Yegya-Raman, N., additional, Wang, D., additional, Li, B., additional, Friedes, C., additional, Iocolano, M., additional, Kao, G.D., additional, Fan, Y., additional, Caruana, R., additional, Feigenberg, S.J., additional, and Xiao, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Multitask AI Models for the Joint Prediction of Overall Survival, Progression-Free Survival, and Death without Progression as a Composite Endpoint for LA-NSCLC Patients Treated with Chemoradiotherapy
- Author
-
Lee, S.H., primary, Yegya-Raman, N., additional, Duan, L., additional, Li, B., additional, Friedes, C., additional, Iocolano, M., additional, Caruana, R., additional, Apte, A., additional, Deasy, J.O., additional, Fan, Y., additional, Kao, G.D., additional, Feigenberg, S.J., additional, and Xiao, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Pneumonitis after Palliative Thoracic Radiotherapy +/- Immunotherapy: A Retrospective Propensity-Matched Cohort Study
- Author
-
Miller, D.G., primary, Yegya-Raman, N., additional, Friedes, C., additional, Cengel, K.A., additional, Plastaras, J.P., additional, Simone II, C.B., additional, Cohen, R., additional, Langer, C., additional, Feigenberg, S.J., additional, and Butala, A.A., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
- Author
-
Yegya-Raman, N., primary, Wright, C.M., additional, Ladbury, C.J., additional, Chew, J., additional, Zhang, S., additional, Sun, S.Y., additional, Burke, S., additional, Baron, J., additional, Sim, A.J., additional, LaRiviere, M.J., additional, Yang, J.C., additional, Robinson, T.J., additional, Tseng, Y.D., additional, Terezakis, S.A., additional, Braunstein, S.E., additional, Dandapani, S.V., additional, Schuster, S., additional, Chong, E.A., additional, Plastaras, J.P., additional, and Figura, N.B., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Interpretable Machine Learning Models for Severe Esophagitis Prediction in LA-NSCLC Patients Treated with Chemoradiation Therapy
- Author
-
Wang, D., primary, Lee, S.H., additional, Yegya-Raman, N., additional, Feigenberg, S.J., additional, Kao, G.D., additional, Largent, A.L., additional, Friedes, C., additional, Iocolano, M., additional, McBeth, R., additional, Duan, L., additional, Li, B., additional, Fan, Y., additional, and Xiao, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
11. Association Between Cardiovascular Substructure Dose and Death Without Progression after Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Kegelman, T.P., additional, Lee, S.H., additional, Kim, K.N., additional, Natarajan, J., additional, Kallan, M.J., additional, Levin, W.P., additional, Cengel, K.A., additional, Kao, G.D., additional, Langer, C., additional, Cohen, R., additional, Aggarwal, C., additional, Singh, A., additional, Adusumalli, S., additional, O'Quinn, R.P., additional, Ky, B., additional, Apte, A., additional, Deasy, J.O., additional, Xiao, Y., additional, and Feigenberg, S.J., additional
- Published
- 2022
- Full Text
- View/download PDF
12. Acute and Long-Term Toxicity of Whole Pelvis Proton Radiation Therapy for Definitive or Adjuvant Management of Gynecologic Cancers
- Author
-
Berlin, E., primary, Yegya-Raman, N., additional, Garver, E.H., additional, Li, T., additional, and Taunk, N.K., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Cytokine Release Syndrome and Neurotoxicity after Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: Is There an Association with Bridging Radiotherapy?
- Author
-
Yegya-Raman, N., primary, Wright, C.M., additional, Zhang, S., additional, Baron, J., additional, LaRiviere, M.J., additional, Gerson, J.N., additional, Nasta, S.D., additional, Barta, S., additional, Chong, E.A., additional, Landsburg, D.J., additional, Svoboda, J., additional, Schuster, S., additional, Xiao, Y., additional, Maity, A., additional, Paydar, I., additional, and Plastaras, J.P., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Cardiac Substructure Dose and Cardiac Events Following Proton- vs. Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
- Author
-
Natarajan, J., primary, Yegya-Raman, N., additional, Kegelman, T.P., additional, Kallan, M.J., additional, Roshkovan, L., additional, Katz, S., additional, Ky, B., additional, Fradley, M., additional, Xiao, Y., additional, Lee, S.H., additional, Zhang, Z., additional, Langer, C., additional, Aggarwal, C., additional, Cohen, R., additional, Cengel, K.A., additional, Levin, W.P., additional, Berman, A.T., additional, and Feigenberg, S.J., additional
- Published
- 2022
- Full Text
- View/download PDF
15. EP08.01-018 Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
- Author
-
Friedes, C., primary, Yegya-Raman, N., additional, Aggarwal, C., additional, Marmarelis, M., additional, Cohen, R., additional, Levin, W., additional, Cengel, K., additional, Ciunci, C., additional, Kosteva, J., additional, Singh, A., additional, Robinson, K., additional, Sun, L., additional, D'Avella, C., additional, Davis, C., additional, Langer, C., additional, and Feigenberg, S., additional
- Published
- 2022
- Full Text
- View/download PDF
16. Salvage Radiotherapy for Relapsed/Refractory Non‐Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor T-Cell (CART) Therapy
- Author
-
Wright, C.M., primary, Yegya-Raman, N., additional, Baron, J., additional, Lee, D.Y., additional, Chong, E.A., additional, LaRiviere, M.J., additional, Maity, A., additional, Plastaras, J.P., additional, and Paydar, I., additional
- Published
- 2021
- Full Text
- View/download PDF
17. MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Kegelman, T., additional, Kim, K., additional, Kallan, M., additional, Levin, W., additional, Cengel, K., additional, Langer, C., additional, Cohen, R., additional, Aggarwal, C., additional, Singh, A., additional, Bauml, J., additional, Adusumalli, S., additional, Denduluri, S., additional, O'Quinn, R., additional, Ky, B., additional, Berman, A., additional, and Feigenberg, S., additional
- Published
- 2021
- Full Text
- View/download PDF
18. Multiple Primary Malignancies in Patients with Anal Squamous Cell Carcinoma
- Author
-
Li, D., primary, Yegya-Raman, N., additional, Kim, S., additional, Ganesan, S., additional, Sayan, M., additional, August, D., additional, Spencer, K., additional, Hathout, L., additional, Maloney-Patel, N., additional, Malhotra, U., additional, Yue, N.J., additional, and Jabbour, S.K., additional
- Published
- 2018
- Full Text
- View/download PDF
19. Impact of Target Volume Margins on Locoregional Control and Acute Toxicity for Unresectable Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Reyhan, M., additional, Kim, S., additional, Deek, M.P., additional, Zou, W., additional, Nie, K., additional, Malhotra, J., additional, Aisner, J., additional, and Jabbour, S.K., additional
- Published
- 2018
- Full Text
- View/download PDF
20. Daily Image-Guidance with Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Kim, S., additional, Deek, M.P., additional, Li, D., additional, Gupta, A., additional, Bond, L., additional, Dwivedi, A.P., additional, Braver, J.K., additional, Reyhan, M., additional, Mittal, A., additional, Gui, B., additional, Malhotra, J., additional, Aisner, J., additional, and Jabbour, S.K., additional
- Published
- 2018
- Full Text
- View/download PDF
21. Five-Year Results of a Prospective Phase 2 Trial Evaluating Three-Week Hypofractionated Whole Breast Radiation Therapy with Boost
- Author
-
Gupta, A., primary, Khan, A.J., additional, Wang, S.J., additional, Yegya-Raman, N., additional, Ahlawat, S., additional, Ohri, N., additional, Goyal, S., additional, Moore, D.F., additional, Eladoumikdachi, F., additional, Toppmeyer, D., additional, and Haffty, B.G., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Dosimetric Predictors of Symptomatic Cardiac Events Among Patients Receiving Conventional-Dose Radiation Therapy for Inoperable Non-Small Cell Lung Cancer
- Author
-
Yegya-Raman, N., primary, Wang, K., additional, Kim, S., additional, Reyhan, M., additional, Deek, M.P., additional, Sayan, M., additional, Malhotra, J., additional, Aisner, J., additional, Patel, M., additional, Marks, L.B., additional, and Jabbour, S.K., additional
- Published
- 2018
- Full Text
- View/download PDF
23. Optimizing Regulatory Reviews for Clinical Protocols that Use Radiopharmaceuticals: Findings of the University of Pennsylvania Radiation Research Safety Committee.
- Author
-
Rhodes SS, Jesikiewicz JE, Yegya-Raman N, Prasad K, Dreyfuss A, Mankoff DA, and Taunk NK
- Abstract
Abstract: Institutional radiation safety committees review research studies with radiation exposure. However, ensuring that the potential patient benefit and knowledge gained merit the radiation risks involved often necessitates revisions that inadvertently delay protocol activations. This quality-improvement study analyzed protocols, identified factors associated with approval time by a radiation safety committee, and developed guidelines to expedite reviews without compromising quality. Clinical protocols submitted to the University of Pennsylvania's Radiation Research Safety Committee (RRSC) for review between 2017 and 2021 were studied. Protocol characteristics, review outcome, stipulations, and approval times were summarized. Statistical analysis (Spearman's rho) was used to investigate stipulations and approval time; rank-sum analysis (Kruskal-Wallis or Wilcoxon) was used to determine whether approval time differed by protocol characteristics. One hundred ten (110) protocols were analyzed. Approximately two-thirds of protocols used approved radiopharmaceuticals to aid investigational therapy trials. Twenty-three percent (23%) of protocols received RRSC approval, and 73% had approval withheld with stipulations, which included requests for edits or additional information. Submissions had a median of three stipulations. Median and mean RRSC approval times were 62 and 80.1 d, and 41% of protocols received RRSC approval after IRB approval. RRSC approval time was positively correlated with stipulations (Spearman's rho = 0. 632, p < 0.001). RRSC approval time was longer for studies using investigational new drugs (median 80 d) than approved radiopharmaceuticals (median 57 d, p = 0.05). The review process is lengthy and may benefit from changes, including publishing standardized radiation safety language and commonly required documents and encouraging timely response to stipulations., (Copyright © 2024 Health Physics Society.)
- Published
- 2024
- Full Text
- View/download PDF
24. Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
- Author
-
Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, and Feigenberg SJ
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Retrospective Studies, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors adverse effects, Lymphopenia etiology, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Radiotherapy, Intensity-Modulated methods, Radiotherapy, Intensity-Modulated adverse effects, Lung Neoplasms pathology, Lung Neoplasms therapy, Lung Neoplasms radiotherapy, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Hospitalization statistics & numerical data, Proton Therapy methods, Proton Therapy adverse effects, Chemoradiotherapy methods, Chemoradiotherapy adverse effects
- Abstract
Introduction: It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation and consolidative immune checkpoint inhibition is associated with fewer unplanned hospitalizations compared with intensity-modulated radiotherapy (IMRT)., Methods: Patients with locally advanced non-small cell lung cancer treated between October 2017 and December 2021 with concurrent chemoradiation with either IMRT or PBT ± consolidative immune checkpoint inhibition were retrospectively identified. Logistic regression was used to assess the association of radiation therapy technique with 90-day hospitalization and grade 3 (G3+) lymphopenia. Competing risk regression was used to compare G3+ pneumonitis, G3+ esophagitis, and G3+ cardiac events. Kaplan-Meier method was used for progression-free survival and overall survival. Inverse probability treatment weighting was applied to adjust for differences in PBT and IMRT groups., Results: Of 316 patients, 117 (37%) received PBT and 199 (63%) received IMRT. The PBT group was older (p < .001) and had higher Charlson Comorbidity Index scores (p = .02). The PBT group received a lower mean heart dose (p < .0001), left anterior descending artery V15 Gy (p = .001), mean lung dose (p = .008), and effective dose to immune circulating cells (p < .001). On inverse probability treatment weighting analysis, PBT was associated with fewer unplanned hospitalizations (adjusted odds ratio, 0.55; 95% CI, 0.38-0.81; p = .002) and less G3+ lymphopenia (adjusted odds ratio, 0.55; 95% CI, 0.37-0.81; p = .003). There was no difference in other G3+ toxicities, progression-free survival, or overall survival., Conclusions: PBT is associated with fewer unplanned hospitalizations, lower effective dose to immune circulating cells and less G3+ lymphopenia compared with IMRT. Minimizing dose to lymphocytes may be warranted, but prospective data are needed., (© 2024 American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
25. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
- Author
-
Akingbemi W, Kurtz G, Yegya-Raman N, Plastaras JP, Schuster SJ, and Chong EA
- Subjects
- Humans, Middle Aged, Combined Modality Therapy methods, Immunotherapy, Adoptive methods, Lymphoma therapy, Lymphoma diagnosis, Neoplasms, Second Primary etiology, Neoplasms, Second Primary diagnosis, Treatment Outcome, Central Nervous System Neoplasms radiotherapy, Central Nervous System Neoplasms therapy, Radiosurgery methods
- Published
- 2024
- Full Text
- View/download PDF
26. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
- Author
-
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, and Yegya-Raman N
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Aged, Adult, Antibodies, Monoclonal therapeutic use, Aged, 80 and over, Survival Rate, Consolidation Chemotherapy, Immune Checkpoint Inhibitors therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Treatment Outcome, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung mortality, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms therapy, Lung Neoplasms mortality, Proto-Oncogene Proteins p21(ras) genetics, Chemoradiotherapy methods, Mutation
- Abstract
Background: Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved progression free survival (PFS) and overall survival (OS) in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI., Methods: In this single-institution, retrospective analysis, we compared treatment outcomes for patients with unresectable KRAS mutated (KRAS-mt) and wild-type (KRAS-wt) NSCLC treated with CRT between October 2017 and December 2021. Kaplan-Meier analysis was conducted comparing median progression free survival and median overall survival from completion of radiotherapy in all KRAS-mt patients and KRAS-G12C-mutated patients. Outcomes were also compared with and without ICI consolidation., Results: Of 156 patients, 42 (26.9%) were KRAS-mt and 114 (73.1%) were KRAS-wt. Baseline characteristics differed only in histology; KRAS-mt NSCLC more likely to be adenocarcinoma. KRAS-mt patients had worse PFS (median 6.3 vs. 10.7 months, P = .041) but similar OS (median 23.1 vs. 27.3 months, P = .237). KRAS-mt patients were more likely to not receive ICI due to rapid disease progression post-CRT (23.8% vs. 4.4%, P = .007). Among patients who received ICI (n = 114), KRAS-mt was not associated with inferior PFS (8.1 vs. 11.9 months, P = .355) or OS (30.5 vs. 31.7 months, P = .692). KRAS-G12C patients (n = 22) had similar PFS and OS to other KRAS-mt., Conclusion: In one of the largest post-CRT KRAS-mt cohort published, KRAS-mt was associated with inferior PFS, largely due to rapid progression prior to ICI consolidation, but did not affect OS. Among those who received ICI consolidation, outcomes were comparable regardless of KRAS-mt status., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
- Author
-
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, and Feigenberg SJ
- Subjects
- Humans, Protons, Prospective Studies, Neoplasm Recurrence, Local, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Re-Irradiation adverse effects, Lung Diseases etiology, Antibodies, Monoclonal, Humanized
- Abstract
Purpose: Reirradiation (reRT) with proton beam therapy (PBT) may offer a chance of cure while minimizing toxicity for patients with isolated intrathoracic recurrences of non-small cell lung cancer (NSCLC). However, distant failure remains common, necessitating strategies to integrate more effective systemic therapy., Methods and Materials: This was a phase 2, single-arm trial (NCT03087760) of consolidation pembrolizumab after PBT reRT for locoregional recurrences of NSCLC. Four to 12 weeks after completion of 60 to 70 Gy PBT reRT, patients without progressive disease received pembrolizumab for up to 12 months. Primary endpoint was progression-free survival (PFS), measured from the start of reRT. Secondary endpoints were overall survival (OS) and National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 toxicity., Results: Between 2017 and 2021, 22 patients received PBT reRT. Median interval from prior radiation end to reRT start was 20 months. Most recurrences (91%) were centrally located. Most patients received concurrent chemotherapy (95%) and pencil beam scanning PBT (77%), and 36% had received prior durvalumab. Fifteen patients (68%) initiated consolidation pembrolizumab on trial and received a median of 3 cycles (range, 2-17). Pembrolizumab was discontinued most commonly due to toxicity (n = 5; 2 were pembrolizumab-related), disease progression (n = 4), and completion of 1 year (n = 3). Median follow-up was 38.7 months. Median PFS and OS were 8.8 months (95% CI, 4.2-23.7) and 22.8 months (95% CI, 6.9-not reached), respectively. There was only one isolated in-field failure after reRT. Grade ≥3 toxicities occurred in 10 patients (45%); 2 were pembrolizumab-related. There were 2 grade 5 toxicities, an aorto-esophageal fistula at 6.9 months and hemoptysis at 46.8 months, both probably from reRT. The trial closed early due to widespread adoption of immunotherapy off-protocol., Conclusions: In the first-ever prospective trial combining PBT reRT with consolidation immunotherapy, PFS was acceptable and OS favorable. Late grade 5 toxicity occurred in 2 of 22 patients. This approach may be considered in selected patients with isolated thoracic recurrences of NSCLC., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
- Author
-
Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, and Yegya-Raman N
- Subjects
- Humans, Immune Checkpoint Inhibitors, Prospective Studies, Chronic Disease, Recurrence, Retrospective Studies, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms therapy
- Abstract
Purpose: The objective of this study was to describe the patterns of failure, frequency of low-volume relapse (LVR), and candidacy for ablative therapy at time of disease progression (PD) after chemoradiation and consolidative immunotherapy (CRT + ICI) in patients with stage III non-small cell lung cancer., Methods and Materials: We identified 229 consecutive patients with stage III non-small cell lung cancer treated with CRT + ICI between October 2017 and December 2021 at a single institution. PD was classified as isolated locoregional failure (LRF), isolated distant failure (DF), or synchronous LRF + DF. Any LRF was subclassified as in-field failure, marginal failure, or out-of-field failure. LVR was defined as 3 or fewer sites of PD in any number of organs. Ablative candidates were defined as having 5 or fewer sites of PD radiographically amenable to high-dose radiation or surgery. Time-to-event data were calculated using cumulative incidence analysis and Kaplan-Meier methods. Multivariable Cox modeling was used to examine the correlations between characteristics of relapse and postprogression survival., Results: Of the 229 patients, 119 (52%) had PD. Of these 119 patients, 20 (21%) had isolated LRF, 28 (24%) had synchronous LRF + DF, and 71 (60%) had isolated DF. Of the 48 patients with any LRF, 28 (58%) had in-field failure, 10 (21%) marginal failure, and 10 (21%) out-of-field failure. The cumulative incidence of LRF and DF was 13% (95% CI, 9.2%-18%) and 32% (95% CI, 26%-38%) at 1 year and 19% (95% CI, 14%-24%) and 39% (95% CI, 33%-46%) at 2 years, respectively. Overall, 64 patients (54%) were considered to have LVR. At time of PD, 60 patients (50%) were eligible for ablative therapy. Patients with LVR had longer median survival versus with high-volume relapse (37.4 vs 15.2 months, P < .001). On multivariable analysis, LVR (hazard ratio, 0.32; 95% CI, 0.18-0.56; P < .001) was associated with improved postprogression survival., Conclusions: After CRT + ICI, approximately half of patients experience LVR at time of PD and are candidates for ablative therapies. Prospective trials are needed to validate the optimal treatment strategy for LVR., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
- Author
-
Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BK, O'Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, and Feigenberg SJ
- Subjects
- Humans, Retrospective Studies, Immunotherapy adverse effects, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms radiotherapy, Radiation Pneumonitis etiology, Radiation Pneumonitis epidemiology, Pneumonia
- Abstract
Purpose: We hypothesized that after adoption of immune checkpoint inhibitor (ICI) consolidation for patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiation therapy (cCRT), rates of symptomatic pneumonitis would increase, thereby supporting efforts to reduce lung radiation dose., Methods and Materials: This single institution, multisite retrospective study included 783 patients with LA-NSCLC treated with definitive cCRT either before introduction of ICI consolidation (pre-ICI era cohort [January 2011-September 2017]; N = 448) or afterward (ICI era cohort [October 2017-December 2021]; N = 335). Primary endpoint was grade ≥2 pneumonitis (G2P) and secondary endpoint was grade ≥3 pneumonitis (G3P), per Common Terminology Criteria for Adverse Events v5.0. Pneumonitis was compared between pre-ICI era and ICI era cohorts using the cumulative incidence function and Gray's test. Inverse probability of treatment weighting (IPTW)-adjusted Fine-Gray models were generated. Logistic models were developed to predict the 1-year probability of G2P as a function of lung dosimetry., Results: G2P was higher in the ICI era than in the pre-ICI era (1-year cumulative incidence 31.4% vs 20.1%; P < .001; IPTW-adjusted multivariable subdistribution hazard ratio, 2.03; 95% confidence interval, 1.53-2.70; P < .001). There was no significant interaction between ICI era treatment and either lung volume receiving ≥20 Gy (V20) or mean lung dose in Fine-Gray regression for G2P; however, the predicted probability of G2P was higher in the ICI era at clinically relevant values of lung V20 (≥24%) and mean lung dose (≥14 Gy). Cut-point analysis revealed a lung V20 threshold of 28% in the ICI era (1-year G2P rate 46.0% above vs 19.8% below; P < .001). Among patients receiving ICI consolidation, lung V5 was not associated with G2P. G3P was not higher in the ICI era (1-year cumulative incidence 7.5% vs 6.0%; P = .39; IPTW-adjusted multivariable subdistribution hazard ratio, 1.12; 95% confidence interval, 0.63-2.01; P = .70)., Conclusions: In patients with LA-NSCLC treated with cCRT, the adoption of ICI consolidation was associated with an increase in G2P but not G3P. With ICI consolidation, stricter lung dose constraints may be warranted., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.
- Author
-
Anstadt EJ, Carmona R, Berlin E, Yegya-Raman N, Venigalla S, Reddy V, Williams GR, Leibensperger MR, Wojcieszynski A, Baumann BC, Lee MK, Plastaras JP, Furth EE, Mell LK, Metz JM, and Ben-Josef E
- Subjects
- Humans, Smad4 Protein genetics, Proportional Hazards Models, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Prognosis, Pancreatic Neoplasms genetics, Pancreatic Neoplasms surgery, Pancreatic Neoplasms metabolism, Adenocarcinoma genetics, Adenocarcinoma surgery
- Abstract
Background: In select patients, pancreatic adenocarcinoma remains a local disease, yet there are no validated biomarkers to predict this behavior and who may benefit from aggressive local treatments. This study sought to determine if SMAD4 (mothers against decapentaplegic homolog 4) messenger RNA-sequencing (RNA-seq) expression is a robust method for predicting overall survival (OS) and distant metastasis-free survival (DMFS) in patients with resected pancreatic adenocarcinoma., Methods: Utilizing The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), 322 patients with resected stage I-III pancreatic adenocarcinoma were identified. In TCGA, multivariable proportional hazards models were used to determine the association of SMAD4 genomic aberrations and RNA-seq expression with OS and DMFS. In the ICGC, analysis sought to confirm the predictive performance of RNA-seq via multivariable models and receiver operator characteristic curves., Results: In TCGA, the presence of SMAD4 genomic aberrations was associated with worse OS (hazard ratio [HR], 1.55; 95% CI, 1.00-2.40; p = .048) but not DMFS (HR, 1.33; 95% CI, .87-2.03; p = .19). Low SMAD4 RNA-seq expression was associated with worse OS (HR, 1.83; 95% CI, 1.17-2.86; p = .008) and DMFS (HR, 1.70; 95% CI, 1.14-2.54; p = .009). In the ICGC, increased SMAD4 RNA-seq expression correlated with improved OS (area under the curve [AUC], .92; 95% CI, .86-.94) and DMFS (AUC, .84; 95% CI, .82-.87)., Conclusions: In patients with resected pancreatic adenocarcinoma, SMAD4 genomic aberrations are associated with worse OS but do not predict for DMFS. Increased SMAD4 RNA-seq expression is associated with improved OS and DMFS in patients with resected pancreatic adenocarcinoma. This reproducible finding suggests SMAD4 RNA-seq expression may be a useful marker to predict metastatic spread., (© 2023 American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
31. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
- Author
-
Yegya-Raman N, Ho Lee S, Friedes C, Wang X, Iocolano M, Kegelman TP, Duan L, Li B, Berlin E, Kim KN, Doucette A, Denduluri S, Levin WP, Cengel KA, Cohen RB, Langer CJ, Kevin Teo BK, Zou W, O'Quinn RP, Deasy JO, Bradley JD, Sun L, Ky B, Xiao Y, and Feigenberg SJ
- Subjects
- Humans, Aged, Immune Checkpoint Inhibitors adverse effects, Retrospective Studies, Radiation Dosage, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Coronary Disease, Cardiovascular Diseases
- Abstract
Purpose: We assessed the association of cardiac radiation dose with cardiac events and survival post-chemoradiation therapy (CRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) after adoption of modern radiation therapy (RT) techniques, stricter cardiac dose constraints, and immune checkpoint inhibitor (ICI) consolidation., Methods and Materials: This single-institution, multi-site retrospective study included 335 patients with LA-NSCLC treated with definitive, concurrent CRT between October 2017 and December 2021. All patients were evaluated for ICI consolidation. Planning dose constraints included heart mean dose < 20 Gy (<10 Gy if feasible) and heart volume receiving ≥ 50 Gy (V50Gy) < 25 %. Twenty-one dosimetric parameters for three different cardiac structures (heart, left anterior descending coronary artery [LAD], and left ventricle) were extracted. Primary endpoint was any major adverse cardiac event (MACE) post-CRT, defined as acute coronary syndrome, heart failure, coronary revascularization, or cardiac-related death. Secondary endpoints were: grade ≥ 3 cardiac events (per CTCAE v5.0), overall survival (OS), lung cancer-specific mortality (LCSM), and other-cause mortality (OCM)., Results: Median age was 68 years, 139 (41 %) had baseline coronary heart disease, and 225 (67 %) received ICI consolidation. Proton therapy was used in 117 (35 %) and intensity-modulated RT in 199 (59 %). Median LAD V15Gy was 1.4 % (IQR 0-22) and median heart mean dose was 8.7 Gy (IQR 4.6-14.4). Median follow-up was 3.3 years. Two-year cumulative incidence of MACE was 9.5 % for all patients and 14.3 % for those with baseline coronary heart disease. Two-year cumulative incidence of grade ≥ 3 cardiac events was 20.4 %. No cardiac dosimetric parameter was associated with an increased risk of MACE or grade ≥ 3 cardiac events. On multivariable analysis, cardiac dose (LAD V15Gy and heart mean dose) was associated with worse OS, driven by an association with LCSM but not OCM., Conclusions: With modern RT techniques, stricter cardiac dose constraints, and ICI consolidation, cardiac dose was associated with LCSM but not OCM or cardiac events in patients with LA-NSCLC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia.
- Author
-
Arkles J, Markman T, Trevillian R, Yegya-Raman N, Garg L, Nazarian S, Santangeli P, Garcia F, Callans D, Frankel DS, Supple G, Lin D, Riley M, Kumaraeswaran R, Marchlinski F, Schaller R, Desjardins B, Chen H, Apinorasethkul O, Alonso-Basanta M, Diffenderfer E, Kim MM, Feigenberg S, Zou W, Marcel J, and Cengel KA
- Subjects
- Humans, Treatment Outcome, Tachycardia, Ventricular, Radiosurgery methods, Amiodarone, Defibrillators, Implantable
- Abstract
Background: Cardiac stereotactic body radiotherapy (SBRT) has emerged as a promising noninvasive treatment for refractory ventricular tachycardia (VT)., Objective: The purpose of this study was to describe the safety and effectiveness of SBRT for VT in refractory to extensive ablation., Methods: After maximal medical and ablation therapy, patients were enrolled in a prospective registry. Available electrophysiological and imaging data were integrated to generate a plan target volume. All SBRTs were planned with a single 25 Gy fraction using respiratory motion mitigation strategies. Clinical outcomes at 6 weeks, 6 months, and 12 months were analyzed and compared with the 6 months prior to treatment. VT burden (implantable cardioverter-defibrillator [ICD] shocks and antitachycardia pacing sequences) as well as clinical and safety outcomes were the main outcomes., Results: Fifteen patients were enrolled and underwent planning. Fourteen (93%) underwent treatment, with 12 (80%) surviving to the end of the 6-week period and 10 (67%) surviving to 12 months. From 6 week to 12 months, there was recurrence of VT, which resulted in either appropriate antitachycardia pacing or ICD shocks in 33% (4 of 12). There were significant reductions in treated VT at 6 weeks to 6 months (98%) and at 12 months (99%) compared to the 6 months before treatment. There was a nonsignificant trend toward lower amiodarone dose at 12 months. Four deaths occurred after treatment, with no changes in ventricular function., Conclusion: For a select group of high-risk patients with VT refractory to standard therapy, SBRT is associated with a reduction in VT and appropriate ICD therapies over 1 year., Competing Interests: Disclosures The authors have no conflicts of interest to disclose., (Copyright © 2023 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
- Author
-
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, and Feigenberg SJ
- Subjects
- Humans, Retrospective Studies, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology
- Abstract
Introduction: The patterns of failure (POF) for metastatic non-small-cell lung cancer (mNSCLC) treated with immunotherapy are not well established., Methods: We conducted a retrospective cohort study of mNSCLC that received first-line pembrolizumab with or without chemotherapy at a single academic center from 2015 to 2021. We defined POF with 2 classifications: 1) local, regional, or distant failure, or 2) failure in existing lesions, new lesions, or a combination. Oligoprogression was defined as disease progression (PD) in ≤3 sites of failure. Overall survival (OS) was measured via Kaplan-Meier and modelled with Cox regression., Results: Of 298 patients identified, 198 had PD. Using POF classification 1, most failures were distant (43.9%) or a combination of locoregional and distant (34.4%). For POF classification 2, failures occurred in a combination of new and existing lesions (45.0%), existing lesions alone (33.3%), or in new lesions only (21.7%). Oligoprogression occurred in 39.9% (n = 79) cases. Median OS was higher in the following: PD in existing lesions vs. new or new + existing lesions (28.7 vs. 20.2 vs. 13.9 months, P < .001) and oligoprogression vs. polyprogression (35.1 vs. 12.2 months, P < .001). In oligoprogression, median OS was better for those who received radiation to all sites of PD (62.2 months) than for those who changed systemic therapy (22.9 months, P = .007). On multivariable analysis, radiation for oligoprogression (HR 0.35, 95% CI: 0.20-0.62, P < .001) was associated with improved OS., Conclusions: In mNSCLC treated with pembrolizumab, oligoprogression is relatively common. Randomized data are needed to define the benefits of radiation in oligoprogressive mNSCLC., Competing Interests: Disclosure LLS: Consulting or Advisory Role: Regeneron, GenMab, Seagen, Baye, Research funding: Blueprint Research, Seagen Research, IO Biotech. CA: Consulting or Advisory Role: AstraZeneca Pharmaceuticals, Merck & Co, Janssen Pharmaceuticals (J&J), Sanofi Genzyme, Pfizer Inc. MEM: Consulting or Advisory Role: AstraZeneca, Blueprint Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Ikena, Janssen, Novocure, TakedaResearch, funding: Eli Lilly, Trizell, AstraZeneca, Stock: Gilead Sciences, Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, Pfizer. RBC: Consulting or Advisory Role: AstraZeneca Pharmaceuticals, CantargiaResearch, Funding: Fstar, Cantargia. CJL: Consulting or Advisory Role: Amgen, AstraZeneca Pharmaceuticals, Takeda Pharmaceuticals, Genentech, Novocure, Regeneron Pharmaceuticals, Pfizer Inc., Sanofi Genzyme Research Funding: Merck & Co, Janssen Pharmaceuticals (J&J), Incyte Corporation., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
34. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
- Author
-
Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP, Cengel KA, Kao G, Teo BK, Langer CJ, Xiao Y, Bradley J, Feigenberg SJ, and Yegya-Raman N
- Subjects
- Humans, Chemoradiotherapy adverse effects, Chemoradiotherapy methods, Radiation Dosage, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymphopenia etiology
- Abstract
Purpose: To explore the association of the effective dose to immune cells (EDIC) with disease control, lymphopenia, and toxicity in patients with non-small cell lung cancer (NSCLC) and identify methods to reduce EDIC., Methods: We abstracted data from all patients with locally advanced NSCLC treated with chemoradiation with or without consolidative immunotherapy over a ten-year period. Associations between EDIC and progression-free survival (PFS) and overall survival (OS) were modeled with Cox proportional hazards and Kaplan-Meier method. Logistic regression was used to model predictors of lymphopenia and higher EDIC. Analyses were performed with EDIC as a continuous and categorical variable. Lymphopenia was graded per CTCAE v5.0., Results: Overall, 786 patients were included (228 of which received consolidative immunotherapy); median EDIC was 4.7 Gy. Patients with EDIC < 4.7 Gy had a longer median PFS (15.3 vs. 9.0 months; p < 0.001) and OS (34.2 vs. 22.4 months; p < 0.001). On multivariable modeling, EDIC correlated with inferior PFS (HR 1.08, 95 % CI 1.01-1.14, p = 0.014) and OS (HR 1.10, 95 % CI 1.04-1.18, p = 0.002). EDIC was predictive of grade 4 lymphopenia (OR 1.16, 95 % CI 1.02-1.33, p = 0.026). EDIC ≥ 4.7 Gy was associated with increased grade 2 + pneumonitis (6-month incidence: 26 % vs 20 %, p = 0.04) and unplanned hospitalizations (90-day incidence: 40 % vs 30 %, p = 0.002). Compared to protons, photon therapy was associated with EDIC ≥ 4.7 Gy (OR 5.26, 95 % CI 3.71-7.69, p < 0.001) in multivariable modeling., Conclusions: EDIC is associated with inferior disease outcomes, treatment-related toxicity, and the development of severe lymphopenia. Proton therapy is associated with lower EDIC. Further investigations to limit radiation dose to the immune system appear warranted., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. Prospective Feasibility and Phase 1/2 Trial of Preoperative Proton Beam Therapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer.
- Author
-
Simone CB 2nd, Yegya-Raman N, Manjunath S, Verma V, Shabason JE, Xu L, Cengel KA, Levin WP, Berman AT, Christodouleas JP, Aggarwal C, Cohen RB, Langer CJ, Pechet TT, Singhal S, Kucharczuk JC, Rengan R, and Feigenberg SJ
- Subjects
- Humans, Feasibility Studies, Prospective Studies, Combined Modality Therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Staging, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms radiotherapy, Lung Neoplasms drug therapy, Proton Therapy adverse effects
- Published
- 2023
- Full Text
- View/download PDF
36. Breast Reconstruction Complications After Postmastectomy Proton Radiation Therapy for Breast Cancer.
- Author
-
Berlin E, Yegya-Raman N, Hollawell C, Haertter A, Fosnot J, Rhodes S, Seol SW, Gentile M, Li T, Freedman GM, and Taunk NK
- Abstract
Purpose: Our purpose was to report complications requiring surgical intervention among patients treated with postmastectomy proton radiation therapy (PMPRT) for breast cancer in the setting of breast reconstruction (BR)., Methods and Materials: Patients enrolled on a prospective proton registry who underwent BR with immediate autologous flap, tissue expander (TE), or implant in place during PMPRT (50/50.4 Gy +/- chest wall boost) were eligible. Major reconstruction complication (MRC) was defined as a complication requiring surgical intervention. Absolute reconstruction failure was an MRC requiring surgical removal of BR. A routine revision (RR) was a plastic surgery refining cosmesis of the BR. Kaplan-Meier method was used to assess disease outcomes and MRC. Cox regression was used to assess predictors of MRC., Results: Seventy-three courses of PMPRT were delivered to 68 women with BR between 2013 and 2021. Median follow-up was 42.1 months. Median age was 47 years. Fifty-six (76.7%) courses used pencil beam scanning PMPRT. Of 73 BR, 29 were flaps (39.7%), 30 implants (41.1%), and 14 TE (19.2%) at time of irradiation. There were 20 (27.4%) RR. There were 9 (12.3%) MRC among 5 implants, 2 flaps, and 2 TE, occurring a median of 29 months from PMPRT start. Three-year freedom from MRC was 86.9%. Three (4.1%) of the MRC were absolute reconstruction failure. Complications leading to MRC included capsular contracture in 5, fat necrosis in 2, and infection in 2. On univariable analysis, BR type, boost, proton technique, age, and smoking status were not associated with MRC, whereas higher body mass index trended toward significance (hazard ratio, 1.07; 95% CI, 0.99-1.16; P = .10)., Conclusions: Patients undergoing PMPRT to BR had a 12.3% incidence of major complications leading to surgical intervention, and total loss of BR was rare. MRC rates were similar among reconstruction types. Minor surgery for RR is common in our practice., Competing Interests: Taoran Li reports grant and honoraria for Varian Medical System and consulting for Boston Scientific. Neil K. Taunk reports grants from Varian Medical Systems and Therapanacea, consulting for Boston Scientific and Point Biopharma, honoraria for Boston Scientific, and an advisory board role for Point Biopharma and Varian Medical Systems., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
37. Statin therapy, cardiac events, and survival in patients with non-small cell lung cancer receiving definitive radiotherapy.
- Author
-
Yegya-Raman N, Friedes C, Iocolano M, and Feigenberg SJ
- Subjects
- Humans, Neoplasm Staging, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Cardiovascular Diseases
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2023
- Full Text
- View/download PDF
38. Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach.
- Author
-
Sherwani Z, Parikh S, Yegya-Raman N, McKenna K, Deek M, Jabbour S, and Hathout L
- Abstract
Historically, the role of radiation in gynecological metastatic disease involved palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has shown survival benefits in oligometastatic disease from varying primary histologies in recent randomized trials. However, gynecologic primary oligometastases have been underrepresented in these trials. Recent studies across gynecological malignancy types have similarly shown favorable outcomes and acceptable toxicities from treating recurrent or oligometastatic gynecologic cancer (ROMGC) patients with definitive radiation therapy. The largest body of literature reported on the use of SBRT in ovarian cancer, which was found to be an effective option, especially in the setting of chemo-resistant disease. Despite the encouraging outcomes using SBRT in oligometastatic gynecologic malignancies, SBRT remains underutilized given the lack of randomized studies studying ROMGC with long term follow-up. While waiting for future prospective trials to establish the role of SBRT as the standard of care in ROMGC patients, this review focuses on reporting the advantages and drawbacks of this technique and examines the current literature to help guide patient centered treatment decisions.
- Published
- 2023
- Full Text
- View/download PDF
39. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
- Author
-
Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, and Feigenberg SJ
- Subjects
- Humans, Retrospective Studies, Neoplasm Staging, Chemoradiotherapy adverse effects, ErbB Receptors therapeutic use, Receptor Protein-Tyrosine Kinases, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Objectives: We sought to determine the proportion of patients with stage III non-small cell lung cancer (NSCLC) who initiate consolidation durvalumab or other immune checkpoint inhibitors (ICIs) after concurrent chemoradiotherapy (cCRT), as well as reasons for nonreceipt and prognostic implications., Materials and Methods: We retrospectively identified consecutive patients with unresectable stage III NSCLC treated with definitive cCRT between October 2017 and December 2021 within a large US academic health system. Patients either received consolidation ICIs (ICI group) or did not (no-ICI group). Baseline characteristics and overall survival (OS) of the groups were assessed. Factors predictive of ICI nonreceipt were evaluated using logistic regression., Results: Of 333 patients who completed cCRT, 229 (69%) initiated consolidation ICIs; 104 (31%) did not. Reasons for ICI nonreceipt included progressive disease post-cCRT (N = 31, 9%), comorbidity or intercurrent illness (N = 25, 8%), cCRT toxicity (N = 23, 7%; 19/23 pneumonitis), and EGFR/ALK alteration (N = 14, 4%). The no-ICI group had worse performance status and a higher rate of baseline pulmonary comorbidity. Larger planning target volume was associated with post-cCRT progressive disease, and higher lung radiation dose with cCRT toxicity. Median OS was 16 months in the no-ICI group and 34.4 months in the ICI group. In the no-ICI group, OS was superior among those with EGFR/ALK alterations (median 44.5 months) and worst among those with progressive disease (median 5.9 months, P < 0.001)., Conclusion: 31% of patients who completed cCRT for stage III NSCLC did not receive consolidation ICIs. Survival amongst these patients is poor, especially for those with progressive disease post-cCRT., Competing Interests: Disclosure ATB - Employment: CVS Health. RBC - Consulting or Advisory Role: AstraZeneca Pharmaceuticals, Cantargia. Research Funding: Fstar, Cantargia. CA - Consulting or Advisory Role: AstraZeneca Pharmaceuticals, Merck & Co, Janssen Pharmaceuticals (J&J), Sanofi Genzyme, Pfizer Inc. MEM - Consulting or Advisory Role: Ikena. Research Funding: Eli Lilly, Merck & Co, AstraZeneca Pharmaceuticals. CJL - Consulting or Advisory Role: Amgen, AstraZeneca Pharmaceuticals, Takeda Pharmaceuticals, Genentech, Novocure, Regeneron Pharmaceuticals, Pfizer Inc., Sanofi Genzyme. Research Funding: Merck & Co, Janssen Pharmaceuticals (J&J), Incyte Corporation., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. A Review of Advances in Radiotherapy in the Setting of Esophageal Cancers.
- Author
-
Cinicola J, Mamidanna S, Yegya-Raman N, Spencer K, Deek MP, and Jabbour SK
- Subjects
- Humans, Radiotherapy Dosage, Chemoradiotherapy adverse effects, Esophageal Neoplasms radiotherapy, Radiotherapy, Intensity-Modulated adverse effects, Proton Therapy adverse effects, Proton Therapy methods
- Abstract
Esophageal cancer is the eighth most common cancer worldwide and is the sixth most common cause of cancer-related mortality. The paradigm has shifted to include a multimodality approach with surgery, chemotherapy, targeted therapy (including immunotherapy), and radiation therapy. Advances in radiotherapy through techniques such as intensity modulated radiotherapy and proton beam therapy have allowed for the more dose homogeneity and improved organ sparing. In addition, recent studies of targeted therapies and predictive approaches in patients with locally advanced disease provide clinicians with new approaches to modify multimodality treatment to improve clinical outcomes., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
- Author
-
Berlin E, Yegya-Raman N, Garver E, Li T, Lin LL, and Taunk NK
- Subjects
- Humans, Female, Middle Aged, Protons, Pelvis, Radiotherapy Dosage, Genital Neoplasms, Female radiotherapy, Genital Neoplasms, Female etiology, Radiotherapy, Intensity-Modulated adverse effects, Proton Therapy adverse effects, Gastrointestinal Diseases etiology, Brachytherapy adverse effects
- Abstract
Objective: To characterize long-term toxicity and disease outcomes with whole pelvis (WP) pencil beam scanning proton radiation therapy (PBS PRT) for gynecologic malignancies., Methods: We reviewed 23 patients treated from 2013 to 2019 with WP PBS PRT for endometrial, cervical, and vaginal cancer. We report acute and late Grade (G)2+ toxicities, graded by Common Terminology Criteria for Adverse Events, Version 5. Disease outcomes were assessed by Kaplan-Meier method., Results: Median age was 59 years. Median follow up was 4.8 years. 12 (52.2%) had uterine cancer, 10 (43.5%) cervical, 1 (4.3%) vaginal. 20 (86.9%) were treated post-hysterectomy. 22 (95.7%) received chemotherapy, 12 concurrently (52.2%). The median PBS PRT dose was 50.4GyRBE (range, 45-62.5). 8 (34.8% had para-aortic/extended fields. 10 (43.5%) received brachytherapy boost. Median follow up was 4.8 years. 5-year actuarial local control was 95.2%, regional control 90.9%, distant control 74.7%, both disease control and progression-free survival 71.2%. Overall survival was 91.3%. In the acute period, 2 patients (8.7%) had G2 genitourinary (GU) toxicity, 6 (26.1%) had gastrointestinal (GI) G2-3 toxicity, 17 (73.9%) had G2-4 hematologic (H) toxicity. In the late period, 3 (13.0%) had G2 GU toxicity, 1 (4.3%) had G2 GI toxicity, 2 (8.7%) had G2-3H toxicity. The mean small bowel V15Gy was 213.4 cc. Mean large bowel V15 Gy was 131.9 cc., Conclusions: WP PBS PRT for gynecologic malignancies delivers favorable locoregional control. Rates of GU and GI toxicity are low. Acute hematologic toxicity was most common, which may be related to the large proportion of patients receiving chemotherapy., Competing Interests: Declaration of Competing Interest There are no conflicts of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
42. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment.
- Author
-
Yegya-Raman N, Berlin E, Feigenberg SJ, Ky B, and Sun L
- Subjects
- Humans, Cardiotoxicity etiology, Cardiotoxicity prevention & control, Cardiotoxicity drug therapy, Lung, Neoplasms drug therapy, Cardiovascular System, Lung Neoplasms complications, Lung Neoplasms radiotherapy, Antineoplastic Agents adverse effects, Cardiovascular Diseases chemically induced, Cardiovascular Diseases prevention & control
- Abstract
Purpose of Review: Patients with lung cancer often have concomitant cardiovascular comorbidities and receive potentially cardiotoxic therapies. As oncologic outcomes improve, the relative impact of cardiovascular disease on lung cancer survivors is expected to increase. This review summarizes cardiovascular toxicities observed after treatment for lung cancer, as well as recommended risk mitigation strategies., Recent Findings: A variety of cardiovascular events may be observed after surgery, radiation therapy (RT), and systemic therapy. The risk of cardiovascular events after radiation therapy (RT) is higher than previously appreciated (23-32%), and RT dose to the heart is a modifiable risk factor. Targeted agents and immune checkpoint inhibitors have been associated with cardiovascular toxicities distinct from those of cytotoxic agents; these are rare but can be severe and require prompt intervention. Optimization of cardiovascular risk factors is important at all phases of cancer therapy and survivorship. Recommended practices for baseline risk assessment, preventive measures, and appropriate monitoring are discussed herein., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
43. Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer.
- Author
-
Natarajan J, Yegya-Raman N, Kegelman TP, Kallan MJ, Roshkovan L, Katz S, Ky B, Fradley M, Xiao Y, Lee SH, Zhang Z, Langer C, Aggarwal C, Cohen R, Cengel K, Levin W, Berman AT, and Feigenberg SJ
- Abstract
Purpose: Radiation therapy (RT) plays a critical role in treating locally advanced non-small cell lung cancer but has been associated with deleterious cardiac effects. We hypothesized that RT dose to certain cardiovascular substructures may be higher among those who experience post-chemoradiation (CRT) cardiac events, and that dose to specific substructures-the great vessels, atria, ventricles, and left anterior descending coronary artery-may be lower with proton- versus photon-based RT., Methods and Materials: In this retrospective review, we selected 26 patients who experienced cardiac events after CRT for locally advanced non-small cell lung cancer and matched them to 26 patients who did not experience cardiac events after CRT. Matching was done based on RT technique (protons vs photons), age, sex, and cardiovascular comorbidity. For each patient, the whole heart and 10 cardiovascular substructures on the RT planning computerized tomography scan were manually contoured. Dosimetric comparisons were made between those who did and did not experience cardiac events and between the proton and photon groups., Results: There was no significant difference in heart or any cardiovascular substructure dose between those patients who experienced post-treatment cardiac events and those who did not ( P > .05 for all). The mean heart dose in the patients receiving proton therapy was significantly lower than the mean heart dose in the patients receiving photon therapy ( P = .032). The left ventricle, right ventricle, and the left anterior descending artery also had significantly lower doses (by multiple measures) when treated with protons ( P = .0004, P < .0001, and P = .0002, respectively)., Conclusions: Proton therapy may have a significant effect on decreasing dose to individual cardiovascular substructures compared with photon therapy. There was no significant difference in heart dose or dose to any cardiovascular substructure between patients who did and did not experience post-treatment cardiac events. Further research should be done to assess the association between cardiovascular substructure dose and post-treatment cardiac events.
- Published
- 2023
- Full Text
- View/download PDF
44. Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer.
- Author
-
Yegya-Raman N, Jabbour SK, and Feigenberg SJ
- Subjects
- Humans, Sinoatrial Node, Radiation Dosage, Atrial Fibrillation complications, Lung Neoplasms complications, Lung Neoplasms radiotherapy
- Published
- 2023
- Full Text
- View/download PDF
45. Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer.
- Author
-
Kim KN, Heintz J, Yegya-Raman N, Cohen R, Kegelman T, Cengel K, Marmarelis M, Sun L, Langer C, Aggarwal C, Singh A, Singhal S, Kucharczuk J, Robinson K, and Feigenberg S
- Subjects
- Humans, Retrospective Studies, Treatment Outcome, Neoplasm Recurrence, Local surgery, Radiotherapy, Adjuvant adverse effects, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Radiotherapy, Conformal, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated methods
- Abstract
Introduction: The role of postoperative radiotherapy (PORT) in patients with resected locally advanced non-small-cell lung cancer (NSCLC) remains controversial due to the radiation techniques used in randomized trials. We conducted a retrospective cohort study evaluating contemporary PORT techniques to evaluate the safety of PORT and risk of death from intercurrent disease ., Materials and Methods: We analyzed consecutive patients with NSCLC treated in a single center that underwent PORT for pN2 disease and/or positive margin, with 3-dimensional conformal radiotherapy (3DRT), intensity modulated radiotherapy , or proton RT (PRT), between 2008 and 2019. Clinical details were collected including intercurrent deaths, defined as death without cancer recurrence. Kaplan-Meier and Cox-Proportional Hazards Models were used., Results: Of 119 patients, 21 (17.6%) received 3DRT, 47 (39.5%) intensity modulated radiotherapy, and 51 (42.9%) PRT. Median follow-up was 40 months (range 8-136) and median RT dose was 5040cGy. Most patients (65.5%) received sequential adjuvant chemoRT; 18.5% received concurrent chemoRT. The rate of grade 3 toxicities was 9.2%. There were 13 (10.9%) deaths from intercurrent diseases, including 6 from second primary cancers and 2 from cardiopulmonary diseases. There were 2 additional deaths from cardiopulmonary disease in patients with cancer progression at time of death. Mean, V5Gy, V30Gy heart doses and mean lung doses were significantly lower with PRT. Three-year OS and disease-free-survival were 70.1% and 49.9%., Conclusion: PORT using contemporary techniques was well tolerated with acceptable toxicity and low rates of intercurrent deaths. Proton therapy significantly reduced heart and lung doses, but radiotherapy modality was not associated with differences in intercurrent disease., Competing Interests: Disclosure The authors have stated that they have no conflicts of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
46. Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
- Author
-
Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, and Plastaras JP
- Abstract
Background and Purpose: CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience of salvage radiotherapy (SRT) in this setting., Materials and Methods: Of 94 patients who received CART therapy from 2018 to 2020, 21 received SRT for post-CART progression. Patients were divided into two groups: locoregional disease (n = 9 [43 %], all disease encompassable within an RT field) and advanced disease (n = 12 [57 %]). Patterns of failure, progression-free survival (PFS), overall survival (OS), and toxicity were assessed., Results: Median time from CART infusion to SRT was 4.0 months (range, 0.6-11.5 months). In the locoregional disease group, 8/9 patients (89 %) were treated with comprehensive SRT to a median dose of 37.5 Gy in a median of 15 fractions. In the advanced disease group, all patients (n = 12) were treated with focal SRT to a median dose of 20.8 Gy in a median of 5 fractions. Median follow-up post-SRT was 15.2 months. In-field response was observed in 8/9 (89 %) in the locoregional disease and 8/9 (89 %) evaluable patients in the advanced disease groups. 17/18 evaluable patients (94 %) patients experienced post-SRT progression, all with a distant component. Median OS was 7.4 months; 21 months for locoregional disease versus 2.4 months for advanced disease (p = 0.0002). Median PFS was 1.1 month, and similarly poor regardless of group. No grade ≥ 3 toxicities occurred., Conclusions: SRT post-CART therapy appears safe with encouraging in-field response but high rates of out-of-field progression, even for those presenting with locoregional disease, highlighting the need for integration of novel systemic agents., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
47. Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer.
- Author
-
Yegya-Raman N, Kegelman TP, Ho Lee S, Kallan MJ, Kim KN, Natarajan J, Deek MP, Zou W, O'Reilly SE, Zhang Z, Levin W, Cengel K, Kao G, Cohen RB, Sun LL, Langer CJ, Aggarwal C, Singh AP, O'Quinn R, Ky B, Apte A, Deasy J, Xiao Y, Berman AT, Jabbour SK, and Feigenberg SJ
- Abstract
Background and Purpose: Prior studies have examined associations of cardiovascular substructure dose with overall survival (OS) or cardiac events after chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC). Herein, we investigate an alternative endpoint, death without cancer progression (DWP), which is potentially more specific than OS and more sensitive than cardiac events for understanding CRT toxicity., Materials and Methods: We retrospectively reviewed records of 187 patients with locally advanced or oligometastatic NSCLC treated with definitive CRT from 2008 to 2016 at a single institution. Dosimetric parameters to the heart, lung, and ten cardiovascular substructures were extracted. Charlson Comorbidity Index (CCI), excluding NSCLC diagnosis, was used to stratify patients into CCI low (0-2; n = 66), CCI intermediate (3-4; n = 78), and CCI high (≥5; n = 43) groups. Primary endpoint was DWP, modeled with competing risk regression. Secondary endpoints included OS. An external cohort consisted of 140 patients from another institution., Results: Median follow-up was 7.3 years for survivors. Death occurred in 143 patients (76.5 %), including death after progression in 118 (63.1 %) and DWP in 25 (13.4 %). On multivariable analysis, increasing CCI stratum and mean heart dose were associated with DWP. For mean heart dose ≥ 10 Gy vs < 10 Gy, DWP was higher (5-year rate, 16.9 % vs 6.7 %, p = 0.04) and OS worse (median, 22.9 vs 34.1 months, p < 0.001). Ventricle (left, right, and bilateral) and pericardial but not atrial substructure dose were associated with DWP, whereas all three were inversely associated with OS. Cutpoint analysis identified right ventricle mean dose ≥ 5.5 Gy as a predictor of DWP. In the external cohort, we confirmed an association of ventricle, but not atrial, dose with DWP., Conclusion: Cardiovascular substructure dose showed distinct associations with DWP. Future cardiotoxicity studies in NSCLC could consider DWP as an endpoint., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
48. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
- Author
-
Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, and Lin SH
- Subjects
- Male, Humans, Cost-Benefit Analysis, Quality-Adjusted Life Years, Radiosurgery methods, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms secondary
- Abstract
It is crucial to economically justify the use of promising therapies such as stereotactic ablative radiotherapy (SABR) for oligometastatic disease (OMD). The goal of this systematic review was to provide a summative evaluation of publications that analyzed the cost-effectiveness (CE) of SABR for OMD. Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided methodology, PubMed and Embase were searched for modeling-based CE studies for various forms of limited metastatic disease. Only full publications that specifically compared SABR with a systemic therapy-based approach were included. In total, 9 studies met inclusion criteria; 4 pertained to OMD with mixed histologies, 2 to oligometastatic non-small cell lung cancer, 1 to pulmonary OMD, 1 to liver OMD, and 1 to low-volume oligorecurrent castration-sensitive prostate cancer. All but 1 investigation illustrated that SABR was cost-effective for the studied population (or a subpopulation); of these studies, the incremental CE ratios for SABR (when reported) ranged from $28,000/quality-adjusted life-year (QALY) to $55,000/QALY. Of studies that reported the probability of SABR being cost-effective at common willingness-to-pay values, the median (range) probability of achieving CE was roughly 61% (30%-88%) at a $50,000/QALY threshold and 78% (31%-100%) at a $100,000/QALY threshold. Taken together, the available evidence suggests that SABR appears to be a cost-effective approach for OMD, which has implications for value-based oncologic practice and construction of future health policies. However, reassessment is required in the context of modern systemic therapies (eg, immunotherapy) as well as long-term follow-up of existing and newly reported randomized trials. Prudent patient selection remains the single most important factor influencing the CE of SABR for OMD., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. Factors Associated With Travel Distance in the Receipt of Proton Breast Radiation Therapy.
- Author
-
Rhodes SS, Berlin E, Yegya-Raman N, Doucette A, Gentile M, Freedman GM, and Taunk NK
- Abstract
Introduction: Proton radiation therapy (PBT) may reduce cardiac doses in breast cancer treatment. Limited availability of proton facilities could require significant travel distances. This study assessed factors associated with travel distances for breast PBT., Materials and Methods: Patients receiving breast PBT at the University of Pennsylvania from 2010 to 2021 were identified. Demographic, cancer, and treatment characteristics were summarized. Straight-line travel distances from the department to patients' addresses were calculated using BatchGeo. Median and mean travel distances were reported. Given non-normality of distribution of travel distances, Wilcoxon rank sum or Kruskal-Wallis test was used to determine whether travel distances differed by race, clinical trial participation, disease laterality, recurrence, and prior radiation., Results: Of 1 male and 284 female patients, 67.8% were White and 21.7% Black. Median travel distance was 13.5 miles with interquartile range of 6.1 to 24.8 miles, and mean travel distance was 13.5 miles with standard deviation of 261.4 miles. 81.1% of patients traveled less than 30 and 6.0% more than 100 miles. Black patients' travel distances were significantly shorter than White patients' and non-Black or non-White patients' travel distances (median = 4.5, 16.5, and 11.3 miles, respectively; P < .0001). Patients not on clinical trials traveled more those on clinical trials (median = 14.7 and 10.2 miles, respectively; P = .032). There was no difference found between travel distances of patients with left-sided versus right-sided versus bilateral disease ( P = .175), with versus without recurrent disease ( P = .057), or with versus without prior radiation ( P = .23)., Conclusion: This study described travel distances and demographic and clinicopathologic characteristics of patients receiving breast PBT at the University of Pennsylvania. Black patients traveled less than White and non-Black or non-White patients and comprised a small portion of the cohort, suggesting barriers to travel and PBT. Patients did not travel further to receive PBT for left-sided or recurrent disease., Competing Interests: Conflicts of Interest: The authors have no relevant conflicts of interest to disclose., (©Copyright 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
50. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy.
- Author
-
Anstadt EJ, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A, Amaravadi RK, Karakousis GC, Cohen JV, Mitchell TC, Schuchter LM, and Lukens JN
- Subjects
- Humans, Ipilimumab adverse effects, Retrospective Studies, Steroids therapeutic use, Colitis chemically induced, Colitis complications, Colitis drug therapy, Melanoma therapy
- Abstract
Background: For patients with melanoma, gastrointestinal immune-related adverse events are common after receipt of anti-CTLA4 therapy. These present difficult decision points regarding whether to discontinue therapy. Detailing the situations in which colitis might predict for improved survival and how this is affected by discontinuation or resumption of therapy can help guide clinical decision-making., Materials and Methods: Patients with stage IV melanoma receiving anti-CTLA4 therapy from 2008 to 2019 were analyzed. Immune-related colitis treated with ≥50 mg prednisone or equivalent daily or secondary immunosuppression was included. Moderate colitis was defined as receipt of oral glucocorticoids only; severe colitis was defined as requiring intravenous glucocorticoids or secondary immunosuppression. The primary outcome was overall survival (OS)., Results: In total, 171 patients received monotherapy, and 91 received dual checkpoint therapy. In the monotherapy group, 25 patients developed colitis and a nonsignificant trend toward improved OS was observed in this group. Notably, when colitis was categorized as none, moderate or severe, OS was significantly improved for moderate colitis only. This survival difference was not present after dual checkpoint therapy. There were no differences in known prognostic variables between groups, and on multivariable analysis neither completion of all ipilimumab cycles nor resumption of immunotherapy correlated with OS, while the development of moderate colitis did significantly affect OS., Conclusion: This single-institution retrospective series suggests moderate colitis correlates with improved OS for patients with stage IV melanoma treated with single-agent anti-CTLA4, but not dual agent, and that this is true regardless of whether the immune-checkpoint blockade is permanently discontinued., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.